In a breakthrough that could transform cancer care, Guardant Health’s new study—RADIOHEAD—suggests that its tissue-free, blood-based test, Guardant Reveal, can detect whether immunotherapy is working months before conventional scans show results. In some cases, it spotted non-responders five months earlier than current standards.
Partnering with the Parker Institute for Cancer Immunotherapy, this study spanned over 500 patients across multiple tumor types. The results? A significant reduction in tumor DNA in the blood predicted better outcomes and lower progression risks—without the need for repeated biopsies or delays in decision-making.
Is this the future of precision oncology? And what does this mean for patients stuck waiting months to see if treatment is working?